Table 5.
Impact of loss of intrinsic aminoglycoside resistance genes on aminoglycoside susceptibility of clinical P. aeruginosa isolates
| Strain | Relevant property | MIC (μg/ml)a |
|||||
|---|---|---|---|---|---|---|---|
| GEN | PAR | SPC | KAN | TOB | AMI | ||
| K2160 | Panaminoglycoside resistant | 32 | 1,024 | 512 | 256 | 8 | 32 |
| K3192 | AmgR− | 8 (4) | 512 (2) | 256 (2) | 64 (4) | 1 (8) | 4 (8) |
| K3193 | PstB− | 8 (4) | 512 (2) | 256 (2) | 64 (4) | 2 (4) | 16 (2) |
| K3194 | FaoA− | 4 (8) | 256 (4) | 256 (2) | 64 (4) | 2 (4) | 8 (4) |
| K3195 | PA2798− | 4 (8) | 256 (4) | 256 (2) | 64 (4) | 1 (8) | 4 (8) |
| K3196 | PA0392− | 4 (8) | 256 (4) | 256 (2) | 64 (4) | 2 (4) | 8 (8) |
| K3197 | LptA− | 8 (4) | 512 (2) | 512 (1) | 128 (2) | 2 (4) | 8 (8) |
| K2168 | MexXY− | 8 (4) | 128 (8) | 64 (8) | 128 (2) | 4 (2) | 8 (8) |
| K2162 | Panaminoglycoside resistant | 256 | >4,096 | 2,048 | 1,024 | 32 | 128 |
| K3198 | AmgR− | 64 (4) | 4,096 (2)b | 1,024 (2) | 512 (2) | 8 (4) | 32 (4) |
| K3199 | PstB− | 16 (16) | 2,048 (4)b | 1,024 (2) | 256 (4) | 16 (2) | 16 (8) |
| K3200 | FaoA− | 64 (4) | 1,024 (8)b | 2,048 (1) | 512 (2) | 16 (2) | 32 (4) |
| K3201 | PA2798− | 8 (32) | 1,024 (8)b | 1,024 (2) | 512 (2) | 4 (8) | 8 (16) |
| K3202 | PA0392− | 16 (16) | 1,024 (8)b | 1,024 (2) | 256 (4) | 8 (4) | 16 (8) |
| K3203 | LptA− | 64 (4) | 4,096 (2)b | 2,048 (1) | 512 (2) | 8 (4) | 32 (4) |
| K2170 | MexXY− | 16 (16) | 256 (32)b | 128 (16) | 256 (4) | 8 (4) | 16 (8) |
a
Fold changes in MIC for the mutants relative to that for the corresponding wild-type clinical parent strain are indicated in parentheses. GEN, gentamicin; PAR, paromomycin; SPC, spectinomycin; KAN, kanamycin; TOB, tobramycin; AMI, amikacin.
b
Because a precise paromomycin MIC was not determined for the K2162 parent of these mutants, the fold change reported in parentheses is a minimum.